PRESTIGE CONSUMER HEALTHCARE INC. Income (Loss) from Continuing Operations, Per Diluted Share
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Income (Loss) from Continuing Operations, Per Diluted Share of $1.27 per share for the 12-month period ending 2013-03-31, per its 10-K filed 2013-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2013-05-17
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for the quarter ending 2012-09-30 was $0.38, a 46.15% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-12-31 was $0.19, a 375.00% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-09-30 was $0.26, a 13.04% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-06-30 was $0.29, a 61.11% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for fiscal 2013 was $1.27, a 73.97% increase from fiscal 2012.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for fiscal 2012 was $0.73, a 25.86% increase from fiscal 2011.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for fiscal 2011 was $0.58, a 9.38% decline from fiscal 2010.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, per diluted share for fiscal 2010 was $0.64.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2013-03-31 | $1.27 10-K · filed 2013-05-17 | |||
| 2012-09-30 | $0.38 10-Q · filed 2012-11-07 | $0.66 10-Q · filed 2012-11-07 | ||
| 2012-03-31 | $0.73 10-K · filed 2013-05-17 | |||
| 2011-12-31 | $0.19 10-Q · filed 2012-02-09 | $0.73 10-Q · filed 2012-02-09 | ||
| 2011-09-30 | $0.26 10-Q · filed 2012-11-07 | $0.55 10-Q · filed 2012-11-07 | ||
| 2011-06-30 | $0.29 10-Q · filed 2011-08-05 | |||
| 2011-03-31 | $0.58 10-K · filed 2013-05-17 | |||
| 2010-12-31 | $0.04 10-Q · filed 2012-02-09 | $0.45 10-Q · filed 2012-02-09 | ||
| 2010-09-30 | $0.23 10-Q · filed 2011-11-09 | $0.41 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $0.18 10-Q · filed 2011-08-05 | |||
| 2010-03-31 | $0.64 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |